As of 12 May 2026, polycystic ovary syndrome (PCOS) has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS), following a global consensus published in The Lancet. The renaming was the result of a 14-year process, with input from more than 14,000 patients and health professionals.
The new name is intended to better reflect that polycystic ovary syndrome (PCOS) is not a condition related to just ovarian cysts, but a lifelong hormonal and metabolic disorder, linked to multiple body systems. The transition to PMOS will occur over a three-year period, with the new name to be fully implemented in the 2028 International Guideline update.
Our friends at Verity charity have shared a letter about this change and what it means for patients - read more here.
